The National Commission for Scheduled Tribes is upset that two important bills that would affect tribals have got the cabinet’s nod without incorporating suggestions given by the panel. “The ministries of mines and rural development failed to consult the NCST as mandated by the Constitution,” commission chairman Rameshwar Oraon told The Telegraph on Wednesday. Secretaries of both ministries had met Oraon, but what the NCST chief meant was the final drafts of...

-The Business Standard   The striking workers at Maruti Suzuki India Limited’s (MSIL) Manesar plant agreed to vacate the factory premise, barely 24 hours after the Punjab and Haryana High Court passed an order asking the workers to move out. In a separate development, the Haryana government referred the strike at MSIL to the labour court for adjudication. The government’s move follows a letter by the MSIL management explaining how the labour unrest...

A fresh public interest litigation (PIL) was filed in the Supreme Court on Friday challenging the United Progressive Alliance (UPA) government’s civil nuclear power programme. The PIL, filed by lawyer Prashant Bhushan on behalf of many former public officials and eminent citizens, makes several demands of the Supreme Court, but most significantly asks it to cancel “clearances given to proposed nuclear power plants and staying all proposed nuclear power plants” till satisfactory...

-The Times of India   Should government-run companies invest in tobacco firms? This is the question that Voices of Tobacco Victims (VoTV), an NGO working for cancer patients, has raised after its recent query under the RTI Act revealed that the Life Insurance Corporation of India has invested up to Rs 3,500 crore in various tobacco companies. "It's the greatest irony that the government spends Rs 10,000 crore on treatment of tobacco-related illnesses...

Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage. It may be pointed out here that as early as...